Related Experiment Video
Updated: Jan 16, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
1.0K
Advanced Immunomodulation in Rheumatoid Arthritis: Immune Checkpoints, microRNAs, and Cell-Based Therapies.
Sandra Pascual-García1, Raúl Cobo1, José Luis Bolinches1
1Department of Biotechnology, University of Alicante, 03690 San Vicente del Raspeig, Spain.
Biomedicines
|September 27, 2025
Summary
Emerging immunomodulatory strategies like immune checkpoints, microRNAs (miRNAs), and cell therapies show promise for treating rheumatoid arthritis (RA). Integrative approaches combined with omics technologies may lead to personalized RA immunotherapy.
Area of Science:
- Immunology
- Rheumatology
- Translational Medicine
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and destruction.
- Current targeted therapies face challenges with treatment response variability and resistance.
- Novel immunomodulatory strategies are needed to improve RA management.
Purpose of the Study:
- To critically evaluate emerging immunomodulatory strategies for rheumatoid arthritis (RA).
- Focus on immune checkpoints, microRNAs (miRNAs), and cell-based therapies.
- Assess their potential as diagnostic and therapeutic tools.
Main Methods:
- Non-systematic literature review of recent studies on RA immunomodulation.
- Analysis of immune checkpoint pathways (CTLA-4, PD-1/PD-L1, ICOS).
- Examination of miRNA-based interventions and cell-based therapies.
Main Results:
- Immune checkpoint modulation shows preclinical efficacy in reducing inflammation and restoring tolerance.
- miRNAs show potential as biomarkers and therapeutics, enhanced by exosome delivery.
- Cell-based therapies demonstrate immunoregulatory effects with good safety.
- Integrated strategies show synergistic effects, particularly when guided by molecular profiling.
Conclusions:
- Targeted immunomodulation, including cell therapies, checkpoint inhibition, and miRNA manipulation, is set to revolutionize RA treatment.
- Integration with omics technologies can enhance precision and safety in personalized immunotherapy.
- Multidisciplinary, patient-centered approaches are crucial for advancing personalized RA immunotherapy.
Related Concept Videos
01:24T Cell Types and Functions
2.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.2K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
01:20The JAK-STAT Signaling Pathway
12.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
12.1K
01:27Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492
01:29Inflammatory Bowel Disease IV: Pharmacological Management
521
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
521